TTRNA-DC vaccines with GM-CSF

Phase 1Vaccine

UUniversity of Florida

TTRNA-DC vaccines with GM-CSF is one of 83 biologic programs targeting Glioma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

OligodendrogliomaActive, not recruiting

MedulloblastomaActive, not recruiting

GliomaPhase 1

Active, not recruiting

OligodendrogliomaPhase 1

Active, not recruiting

MedulloblastomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

394 competitors in Glioma

#DrugCompanyPhaseTrials

Paraplatin

AAvyxa

Phase 3

15 2

Trexall

Alnylam Pharmaceuticals

Phase 3

2 3

Tepadina

Alnylam Pharmaceuticals

Phase 3

1 4

Bicnu

MMelissa K Accordino

Phase 3

7 5

Vepesid

AAvyxa

Phase 3

4 6

Accutane

CConrado Roberto Hoffmann Filho

Phase 3

1 7

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 8

Rayos

RRoxane Laboratories

Phase 3

1 9

Selumetinib /m2

NNational Cancer Institute (NCI)

Phase 3

1 10

Luvometinib

SShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Active, not recruiting

Oligodendroglioma

NCT06254326

Q4 2028

Phase 1Active, not recruiting

Medulloblastoma

NCT06514898

Clinical

Trials by Indication[1]

Glioma2 trials

Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas

Terminated·UUniversity of Florida·Phase 1·NCT03334305·18 enrolled

Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)

Terminated·UUniversity of Florida·Phase 1·NCT03396575·11 enrolled

Medulloblastoma1 trial

Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma

Active, not recruiting·UUniversity of Florida·Phase 1·NCT06514898·12 enrolled

Oligodendroglioma1 trial

ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients

Active, not recruiting·UUniversity of Florida·Phase 1·NCT06254326·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for TTRNA-DC vaccines with GM-CSF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TTRNA-DC vaccines with GM-CSF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TTRNA-DC vaccines with GM-CSF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Florida company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Florida

TTRNA-DC vaccines with GM-CSF

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q4 2028

Trials by Indication[1]

Glioma2 trials

Medulloblastoma1 trial

Oligodendroglioma1 trial

References

Drug Info

Quick Facts

Related News